A Comparative Analysis of the Impact of a Positive List System on New Chemical Entity Drugs and Incrementally Modified Drugs in South Korea

Clinical Therapeutics

Volumn 33, Issue 7, 2011, Pages 926-932

  Ha, DongMun ^a   Choi, Yong ^a   Kim, Dae Up ^a   Chung, Kyu Hyuck ^a   Lee, Eui Kyung ^b  

^a Sungkyunkwan University   (South Korea)

^b Sookmyung Women's University   (South Korea)

Author keywords

Cost effectiveness; Drug listing; Incrementally modified drugs (IMD); New drug; Positive list

Indexed keywords

DRUG; INCREMENTALLY MODIFIED DRUG; NEW CHEMICAL ENTITY DRUG; UNCLASSIFIED DRUG;

ARTICLE; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DATA BASE; DRUG COST; HEALTH CARE SYSTEM; HEALTH INSURANCE; LOGISTIC REGRESSION ANALYSIS; PARAMETER; POSITIVE LIST SYSTEM; REIMBURSEMENT; SOUTH KOREA; STATISTICAL SIGNIFICANCE;

DATABASES, FACTUAL; DRUG COSTS; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; INSURANCE, PHARMACEUTICAL SERVICES; LOGISTIC MODELS; NATIONAL HEALTH PROGRAMS; REIMBURSEMENT MECHANISMS; REPUBLIC OF KOREA; TIME FACTORS;

EID: 79960271881     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.05.089     Document Type: Article

References (20)

1. Policy Measures to Optimize Drug Expenditure 2006, Ministry of Health Welfare and Family, Ministry of Health Welfare and Family, Gwacheon.
2. Lee E.K., Park B.S., Park S.J., et al. Policy measures to improve drug benefit program with positive list 2005, Korea Institute for Health and Social Affairs, Seoul.
3. Improving Public Health Through Human Drugs 2007, US Food and Drug Administration Center for Drug Evaluation and Research, Silver Spring, MD.
4. Bae E.Y., Lee E.K. Pharmacoeconomic guidelines and their implementation in the positive list system in South Korea. Value Health 2009, 12(Suppl 3):S36-S41.
5. Health Insurance Review and Assessment Service's (HIRA) Homepage Accessed December 31, 2008. http://www.hira.or.kr/common/dummy.jsp?pgmid=HIRAV010300000000.
6. Ministry of Health and Welfare Homepage Accessed June 31, 2009. http://english.mw.go.kr/front/jb/sjb0402ls.jsp?PAR_MENU_ID=03%26MENU_ID=030402.
7. Article 2-8 of the pharmaceutical affairs law February 29, 2008, Ministry of Health Welfare and Family, Ministry of Health Welfare and Family, Gwacheon.
8. The Korea Food and Drug Administration order: The Regulation of Licensed item. Registration Evaluation of Drug August 14, 2008, Korea Food and Drug administration, Korea Food and Drug Administration, Cheongwon.
9. Lee J., Jeong B.S., Kim M.S., et al. Comparison between logistic regression and artificial neural networks as MMPI discriminator. Korean J Biol Psychiatry 2005, 12:165-172.
10. Dreiseitl S., Ohno-Machado L. Logistic regression and artificial neural network classification models: a methodology review. J Biomed Inform 2002, 35:352-359.
11. Internal report April 2008, Health Insurance Review & Assessment Service's (HIRA).
12. Detailed Guidelines for the Assessment of Cost-Effectiveness of Incrementally Modified Drugs 2007, Ministry of Health and Welfare, Ministry of Health Welfare and Family, Gwacheon.
13. Jeong S.H. The implication of incrementally modified drug technology and the current trends in psycho-pharmacology. Korean J Psychopharmacol 2007, 18:373-383.
14. The fourth Meeting of Drug Reimbursement Evaluation Committee (DREC). Detailed guidelines for the assessment of cost-effectiveness of incrementally modified drugs 2008, Health Insurance Review and Assessment Service's (HIRA), Health Insurance Review and Assessment Service's (HIRA), Seoul.
15. Lee E.K., Jeong Y.H., Yu K.C., et al. Policy directions to facilitate the economic evaluation of new health technologies: focused on pharmaceuticals December 2005, Korea Institute for Health and Social Affairs, Seoul.
16. Yang B.M., Bae E.Y., Kim J.H., et al. Economic evaluation and pharmaceutical reimbursement reform in South Korea's National Health Insurance. Health Aff (Millwood) 2008, 27:179-187.
17. PausJenssen A.M., Singer P.A., Detsky A.S. Ontario's formulary committee: how recommendations are made. Pharmacoeconomics 2003, 21:285-294.
18. Ontario Guidelines for Economic Analysis of Pharmaceutical Products August 1994, Ontario Ministry of Health, Ontario Ministry of Health, Toronto, Ontario.
19. Detsky A.S. Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada. Pharmacoeconomics 1993, 3:354-361.
20. Naylor C.D., Williams J.I., Basinski A., Goel V. Technology assessment and cost-effectiveness analysis: misguided guidelines?. CMAJ 1993, 148:921-924.